Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Chad M. Robins filed a Rule 144 notice to sell 124,998 shares of common stock, with an aggregate market value of $2,298,713.22, through Goldman Sachs & Co. LLC on or about 02/02/2026 on the NASD exchange.
The shares include stock acquired as performance-based compensation on 03/04/2022 (119,419 shares) and earlier founder’s shares from 09/01/2009 (5,579 shares). The issuer had 152,665,188 shares outstanding. Robins has already completed multiple common stock sales in recent months between 11/10/2025 and 01/05/2026.
BlackRock, Inc. has filed an amended Schedule 13G showing a significant institutional position in Adaptive Biotechnologies Corp common stock. BlackRock reports beneficial ownership of 11,992,448 shares, representing 7.9% of the outstanding common stock. It has sole power to vote 11,764,835 of these shares and sole power to dispose of all 11,992,448 shares, with no shared voting or dispositive power.
BlackRock classifies itself as a holding company and states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Adaptive Biotechnologies. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single person has more than five percent of the issuer’s total outstanding common shares.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and a share sale in company stock. On January 12, 2026, Lo exercised several stock options, acquiring 36,650 shares at $7.80, 7,723 shares at $12.14, 21,002 shares at $8.46, and 14,215 shares at $3.99 per share. The same day, Lo sold 79,590 shares of common stock at $17.73 per share. After these transactions, Lo directly owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, and that the reported options are fully or time-vested according to their respective vesting schedules.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported an option exercise and share sale in company stock. On January 12, 2026, he exercised stock options for 4,290 shares of common stock at an exercise price of $12.14 per share, receiving 4,290 shares.
On the same date, he sold 4,290 shares of common stock at a price of $18 per share, leaving him with 216,637 shares of common stock held directly after the transactions. The filing notes these trades were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following the exercise, 4,291 stock options remained beneficially owned.
A holder of ADPT common stock has filed a notice of proposed sale under Rule 144 for 64,293 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an aggregate market value of 1,013,257.68. These shares were acquired on 01/12/2026 via a cash exercise of stock options from the issuer, with payment also made on that date.
The notice also lists prior Rule 10b5-1 sales for Francis Lo over the past three months, including a sale of 113,890 common shares on 12/15/2025 for gross proceeds of 1,773,381.19, along with additional smaller sales on 12/22/2025 and 01/02/2026. By signing, the seller represents not knowing any undisclosed material adverse information about the issuer.
Adaptive Biotechnologies security holder files a Form 144 notice to sell common stock. The filing covers a proposed sale of 11,081 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $174,636.56 and an approximate sale date of 01/12/2026.
The shares to be sold were acquired through stock option exercises, including 8,581 shares exercised for cash on 01/12/2026 and 2,500 shares previously exercised for cash on 03/14/2025. Over the past three months, the person for whose account the securities are to be sold has already sold common shares, including 162,820 shares on 11/28/2025 for gross proceeds of $3,174,534.10 and 238 shares on 11/17/2025 for $3,343.90, with one entry identified as 10b5-1 sales.
Adaptive Biotechnologies Corporation reported that it issued a press release with its financial results for the quarter and year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report. The company also furnished an investor presentation, dated the same day, as Exhibit 99.2, which management may use in meetings with investors and analysts. Both the earnings release and the presentation are being furnished rather than filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins sold 10,000 shares of common stock on January 6, 2026. The sale was reported at a weighted average price of $16.44 per share. According to the disclosure, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. After this sale, he beneficially owned 1,222,312 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies officer Francis Lo, the Chief People Officer, reported option exercises and a related stock sale for company shares. On December 22, 2025, Lo exercised stock options to acquire 1,100 shares at $7.80, 1,100 shares at $8.46, and 2,194 shares at $3.99 per share, then sold 4,394 shares of common stock at a weighted-average price of $17.50. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo directly beneficially owned 315,978 shares of common stock and held additional indirect ownership of 2,500 shares through spouse You Jin Lee, along with multiple remaining stock option positions.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported selling 124,998 shares of the company’s common stock on January 5, 2026 at a weighted average price of $15.59 per share. After this sale, he beneficially owned 2,584,243 shares directly.
The transaction was coded as an open market or private sale and was carried out under a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. The filing notes that the shares were sold in multiple trades at prices ranging from $15.31 to $15.96, and that detailed trade-by-trade information is available upon request.